Vontobel Holding
TVTX icon

Vontobel Holding’s Travere Therapeutics TVTX Stock Holding History

Vontobel Holding’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,800
Closed -$98.7K – 1148
2024
Q1 		$98.7K Sell
12,800
-274,623
-96% -$2.32M ﹤0.01% 1023
2023
Q4 		$2.58M Buy
+287,423
New +$2.09M 0.02% 392

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Vontobel Holding's TVTX Position: Q2 2024 in Review

Vontobel Holding sold out of Travere Therapeutics (TVTX) in Q2 2024, closing a stake of 12,800 shares — an estimated $98.7K sold.

Vontobel Holding first reported a position in TVTX in Q4 2023 and held it in 2 quarters. The position peaked at $2.58M in Q4 2023. 173 funds tracked by Wall St. Rank hold TVTX as of Q2 2024.

  • Vontobel Holding reported no remaining Travere Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Vontobel Holding sold 12,800 Travere Therapeutics shares in Q2 2024, an estimated $98.7K.
  • Vontobel Holding first reported a position in Travere Therapeutics in Q4 2023 and held it in 2 quarters.
  • Vontobel Holding's Travere Therapeutics position peaked at $2.58M in Q4 2023.
  • 173 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2024.

Based on Vontobel Holding's 13F filing for Q2 2024, filed 13 Aug 2024.